Navigation Links
YM BioSciences third quarter 2010 operational and financial results
Date:5/13/2010

clinical trials; that JAK 1/2 and the VDA molecule will generate positive efficacy and safety data in future clinical trials; AeroLEF(R) will continue to generate positive efficacy and safety data in future clinical trials; that and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. Except as required by applicable securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

    YM BIOSCIENCES INC.
    Interim Consolidated Balance Sheets
    (Expressed in Canadian dollars, unless otherwise indicated)

    -------------------------------------------------------------------------
                                                    March 31,        June 30,
                                                        2010            2009
    -------------------------------------------------------------------------
                                                  (Unaudited)
    Assets

    Current assets:
      Cash                                      $  27,862,417  $   2,337,716
      Short-term deposits                          20,149,367     39,713,042
      Accounts receivable                             390,714        564,584
      Prepaid expenses                                129,589        352,850
      -----------------------------------------------------------------------
                                                   48,532,087     42,968,192

    Property and equipment                             95,794         96,876

    Intangible assets                              14,982,168      3,004,868

    -------------------------------------------------------------------------
                                                $  63,610,049  $  46,069,936
    -------------------------------------------------------------------------
    ---------------------------
'/>"/>
SOURCE YM BioSciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
2. Regado Biosciences to Present at the BIO International Convention Held in Chicago, Illinois on May 5, 2010
3. YM BioSciences announces controlled equity offering
4. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
5. NeoStem, Inc. and ImmuneRegen BioSciences(R) Announce a Collaborative Agreement to Advance Stem Cell Technology
6. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
7. YM BioSciences announces AACR acceptance of two nimotuzumab poster presentations
8. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
9. YM BioSciences closes US$17.5 million financing
10. YM BioSciences to raise approximately US$15 million
11. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Bryan-College Station, Texas (PRWEB) September 18, 2014 ... University System Chancellor John Sharp, Texas A&M Health ... from the U.S. Department of Health and Human ... GSK today dedicated a national pandemic influenza vaccine ... will serve as an anchor for the Texas ...
(Date:9/18/2014)... , Sept. 18, 2014 Research ... "Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, ... report to their offering. The global ... CAGR of 22.7% from 2014 to 2019. Factors such ... growing adoption of companion diagnostics by the pharmaceutical industry, ...
(Date:9/18/2014)... 18, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... concurrent but separate underwritten offerings of 10,000,000 shares of ... of $2.00 per share, for expected gross proceeds of ... Convertible Preferred Stock at a price to the public ... $20 million. Each share of Series A Convertible Preferred ...
(Date:9/18/2014)... diseases that afflict skeletal growth through abnormalities in ... fetal stage and is caused by genetic mutations. ... factor receptor 3 (FGFR3) has been associated with ... a skeletal dysplasia that cause serious respiratory problems ... (ACH), which causes stunted growth and other complications ...
Breaking Biology Technology:Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 2Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 3Texas A&M Dedicates National Pandemic Influenza Vaccine Manufacturing Facility, on Track for 2016 Start-Up Phase 4Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 2Oncothyreon Prices $40 Million Concurrent Public Offerings of Common Stock and Preferred Stock 3Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3
... Arpida Ltd,(SIX: ARPN) announced today its financial results for the six ... to date, - Regulatory setback for intravenous iclaprim in ... - Company restructuring completed, , Cash ... CFO Harry Welten, MBA, commented: "Our cost-saving measures ...
... , , , , ... the healthcar e field using technology in ... patient care, what isn,t clear is the exact role technology will play ... the right information, be it clinical or administrative, at the right time, ...
... particles have been used to bring stem cells to ... to increase the capacity of cells to repair damaged ... disciplinary research, published in The Journal of the ... technique where endothelial progenitor cells a type of ...
Cached Biology Technology:Arpida Reports Interim Results For Six Months to 30 June 2009 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 2Healthcare Continues to Use OnBase in 'Meaningful' Ways 3Healthcare Continues to Use OnBase in 'Meaningful' Ways 4Nanomagnets guide stem cells to damaged tissue 2
(Date:9/18/2014)... that prompts millions of Americans to undertake jaunts into the ... a little longer within a century, according to new research. ... areas of the United States as summer temperatures linger later ... Global Ecology and Biogeography . For instance, the paper ... tree of New Hampshire could change color one to ...
(Date:9/18/2014)... genetic information is stored in DNA, tiny strands of ... our bodies. To express this genetic data, our DNA ... instructions into proteins that perform tasks in our cells. ... type of RNA molecule. Unlike all other known RNAs, ... Although circRNA molecules are abundant, little has been known ...
(Date:9/18/2014)... AZ, Sept. 18, 2014 -- Arizona turned its newborn ... just a few short months, earning it the first-ever Newborn ... The March of Dimes presented Will Humble, M.P.H., Arizona,s Department ... held here today. Mr. Humble established a policy of full ... to send newborn blood samples to the lab for analysis, ...
Breaking Biology News(10 mins):Fall foliage season may be later, but longer on warmer Earth 2Fall foliage season may be later, but longer on warmer Earth 3Fall foliage season may be later, but longer on warmer Earth 4Scientists find how mysterious 'circular RNA' is formed, claim muscular dystrophy link 2March of Dimes honors Arizona with first-ever newborn screening award 2March of Dimes honors Arizona with first-ever newborn screening award 3
... rise, so does the pressure on the plant kingdom. The ... will absorb some of the extra CO 2 and ... now, researchers have hypothesized about one major roadblock: nitrogen. ... they take up from the atmosphere. The more they get, ...
... Wash.There really is a balance of nature, but as accepted ... Washington State University researchers writing in the journal Nature ... typical of organic farms work better at fighting pests and ... pests and their natural enemies in potatoes and found organic ...
... Alberta, June 30, 2010 Innovotech Inc. (TSX-V: IOT), ... has secured funding in excess of $900,000 from Agriculture ... its unique, environmentally friendly seed treatment and plant spray ... infections. "With the potential to increase crop yields ...
Cached Biology News:Nitrogen pollution alters global change scenarios from the ground up 2Nitrogen pollution alters global change scenarios from the ground up 3'Balanced' ecosystems seen in organic ag better at controlling pests 2
...
prototype Nco I...
Based on Silica membrane matrix beads. The kit is designed for the purification of DNA (20 bp - 100 bp) from TAE/TBE agarose gels. Run time is approximately 45 minutes....
Modified and insect cell culture tested....
Biology Products: